Results

Total Results: 3,085 records

Showing results for "drug".

41. Infographic - More Opioid-Related Emergency Visits, No Change in Illicit Drug Use Treatment (pdf file)
    www.ahrq.gov/sites/default/files/wysiwyg/data/infographics/emergency-visits-opioids.pdf
    September 27, 2021 - Infographic - More Opioid-Related Emergency Visits, No Change in Illicit Drug Use Treatment This Is … Health Services Administration, Center for Behavioral Health Statistics and Quality, National Survey on Drug … More Opioid-Related Emergency Visits, No Change in Illicit Drug Use Treatment Emergency Department … Visits for Opioid- Related Care Getting Treatment for Illicit Drug Use When Needed People Ages

42. National Quality Strategy Agency-Specific Plan: Food and Drug Administration (FDA) (pdf file)
    www.ahrq.gov/sites/default/files/wysiwyg/workingforquality/fda-specific-plan_nqs2013.pdf
    June 25, 2013 - National Quality Strategy Agency-Specific Plan: Food and Drug Administration (FDA) Agency-Specific … Plans for the National Quality Strategy Food and Drug Administration (FDA) 1 AGENCY-SPECIFIC PLAN … FOR THE NATIONAL QUALITY STRATEGY Food and Drug Administration (FDA) Program Description NQS Priorities … Preventable drug harm will be reduced through increased communication, engagement, and action across … • Expand intervention initiative to prevent drug harm through public and private collaborations

43. Final Progress Report: TOP-MEDS CERT: Tools for Optimizing Medication Safety (pdf file)
    www.ahrq.gov/sites/default/files/2024-01/lambert-report.pdf
    January 01, 2024 - , and patient-centered drug information. … Key Words: Medication safety, adverse drug events, statistical methods, opioid dosing, simulation, drug … In the context of drug safety, the discrete-time survival model allows us to use drug exposure as a … Regulators and drug companies seeking a validated pre-approval method for identifying confusing drug … to Drug A exceeds a threshold; and (3) Drug B has an indication that matches an active diagnosis (e.g

44. Final Progress Report: Risk-Informed Intervention to Improve Ambulatory Drug Monitoring and Safety (pdf file)
    www.ahrq.gov/sites/default/files/2024-01/field-report.pdf
    January 01, 2024 - of preventable adverse drug events in the ambulatory setting; 41% of preventable, serious adverse drug … causes of preventable adverse drug events in this setting; 41% of preventable, serious adverse drug … The unit of analysis was the drug-test pair. … Chronic users of a drug were less likely to skip a test, as were those taking more than one study drug … process to select guideline medications based on the importance of monitoring for efficacy, safety, and drug-drug

45. Final Progress Report: Off-Label Prescribing: Comparative Evidence, Regulation, and Utilization (pdf file)
    www.ahrq.gov/sites/default/files/2024-01/kesselheim-report.pdf
    January 01, 2024 - of off-label drug use and medical, social, legal, and economic factors that influence off-label drug … Drug Safety. 2002;25:1- 5. 5 Rayburn W, Turnbull G. … Pharmacoepidemiol Drug Saf. 2005;14(9):629-638. 9 Food and Drug Administration. … ineffective off-label drug use, potentially dangerous off-label drug use, and off-label uses encouraged … Drug labels: a flawed source of data for studying orphan drug approvals.

46. Evaluation of a Medication Therapy Management Program in Medicare Beneficiaries at High Risk of Adverse Drug Events: Study Methods (pdf file)
    www.ahrq.gov/sites/default/files/wysiwyg/professionals/quality-patient-safety/patient-safety-resources/resources/advances-in-patient-safety-2/vol4/Advances-Masica_112.pdf
    November 30, 2010 - drug plans and Medicare Advantage plans offering prescription drug coverage have a medication therapy … problems Pharmaceutical care network Europe drug assessment formb Communication of drug-related problems … Improving drug use in elderly patients: Getting to the next level. … Drug-related problem classification systems. … A method for estimating the probability of adverse drug reactions.

47. Impact of Medicaid Policy on Cardiovascular Drug Use and Clinical Outcomes | Agency for Healthcare Research and Quality
    www.ahrq.gov/practiceimprovement/delivery-initiative/abstract-fischer.html
    December 01, 2017 - Impact of Medicaid Policy on Cardiovascular Drug Use and Clinical Outcomes Abstract Principal … The first set includes requiring prior authorization and use of preferred drug lists, typically for four … Data on aggregate drug use came from publicly available files provided by the Centers for Medicare & … Results While prescription drug reimbursement policies varied widely across Medicaid programs, States … the study period), only a small percentage of States used prior authorization policies and preferred drug

48. Final Progress Report: Clinical Prediction of Hepatotoxicity & Comparative Hepatic Safety of Medications (pdf file)
    www.ahrq.gov/sites/default/files/2024-01/lo-report.pdf
    January 01, 2024 - suspected drug-induced liver injury within KPNC at the initial drug-induced liver injury diagnosis … Drug-induced liver disorders: implications for drug development and regulation. … US Food and Drug Administration. … Rules and laws of drug hepatotoxicity. Pharmacoepidemiol Drug Saf 2006;15:231-3. 13. Lewis JH. … US Food and Drug Administration Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole)

49. Final Progress Report: Clinical importance of the drug interaction between statins and CYP3A inhibitors (pdf file)
    www.ahrq.gov/sites/default/files/wysiwyg/research/findings/final-reports/17358-Strom-draft-1.pdf
    June 30, 2010 - inhibitors, renal dysfunction, hepatic dysfunction, muscle toxicity, myopathy, myalgia, rhabdomyolysis, drug-drug … 11% 10% 10% 8% 11% 10% Hypertension drug 63% 64% 57% 60% 63% 65% Thyroid drug 7% 7% 6% 6% 7% 7% Gemfibrozil … pharmacodynamic alterations of 3-hydroxy- 3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug-drug … Drug Interactions: Cytochrome P450 Drug interaction table: Indiana University School of Medicine 2007 … Drug Safety. 2008;31(3):231-240.

50. Consumer Reports Uses AHRQ Research in Drug Purchasing Recommendations | Agency for Healthcare Research and Quality
    www.ahrq.gov/news/newsroom/case-studies/coe0705.html
    October 01, 2014 - Consumer Reports Uses AHRQ Research in Drug Purchasing Recommendations Search All Impact Case Studies … The magnitude of the EHC program's impact is evidenced by the fact that the Consumers Union drug class … Assisting patients and physicians in making informed decisions regarding prescription drug choices not

51. Development of a Computerized Adverse Drug Event (ADE) Monitor in the Outpatient Setting (pdf file)
    www.ahrq.gov/sites/default/files/wysiwyg/professionals/quality-patient-safety/patient-safety-resources/resources/advances-in-patient-safety/vol2/Seger.pdf
    January 01, 2003 - We also drew from Micromedex® to develop a focused list of drug-drug interactions to be incorporated … The first category (drug) involved the use of medication data. … of 2 drugs together (DDIs) Drug Duplicate therapy (2 active ACE inhibitors) Drug Duplicate therapy … and a CK > 500 Drug-lab Receiving phenytoin and no phenytoin test within the past 12 months Drug-lab … Incidence of adverse drug events and potential adverse drug events: Implications for prevention.

52. Final Progress Report: Prescribing Errors in Ambulatory Pediatric Care (pdf file)
    www.ahrq.gov/sites/default/files/2024-01/basco-report.pdf
    January 01, 2024 - For 11 LASA drug pairs, we identified patients who experienced a first dispensing of one drug in the … LASA errors are the erroneous prescription or delivery of a drug because the name of the drug (generic … (a "usual drug"). … and then presented with a first prescription for the paired drug within 6 months of a usual drug. … Either drug in a LASA pair could serve as the usual drug.

53. Final Progress Report: Optimizing OTC labels for older adults (pdf file)
    www.ahrq.gov/sites/default/files/2024-11/becker-bix-report.pdf
    January 01, 2024 - Results: Survey results indicated that drug-drug and drug-diagnosis warnings were critical to ADE prevention … In brief, the information in this critical subset were the warnings concerning drug/drug and drug-diagnosis … The highlighting treatment will involve highlighting the active ingredient and all drug- drug and drug-diagnosis … as a potential drug- drug interaction, a potential drug-diagnosis interaction, or another problem (e.g … /drug and drug/diagnosis warnings) were most important.

54. CHIPRA 212 Appendix 1 (pdf file)
    www.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-212-appendix-1.pdf
    January 24, 2025 - Accuneb Asthma Drug Albuterol Sulfate Asthma Drug Proventil Asthma Drug ProAir HFA Asthma Drug ReliOn … Ventolin HFA Asthma Drug Ventolin HFA Asthma Drug Qvar Asthma Drug Budesonide Asthma Drug Pulmicort … Respules Asthma Drug Symbicort Asthma Drug Alvesco HFA Asthma Drug Cromolyn Sodium Asthma Drug Flovent … Diskus Asthma Drug Advair Diskus Asthma Drug Dulera Asthma Drug Levalbuterol Asthma Drug Xopenex … Asthma Drug Metaproterenol Sulfate Asthma Drug Asmanex Twisthaler 30 Dose

55. Final Progress Report: Encoding and Processing Patient Allergy Information in EHRs (pdf file)
    www.ahrq.gov/sites/default/files/2024-07/zhou-report.pdf
    January 01, 2024 - For example, a mention of a drug name may be in reference to that drug as an allergen, but it could … For example, if a drug name was mentioned in the allergy section, we could infer that the drug belongs … The prevalence of each drug and drug class was calculated and compared by sex and race/ethnicity. … of 1.95 drug allergies per patient. … to ≥2 drug classes.

56. Final Progress Report: Medication Safety in Primary Care Practice Translating Research Into Practice (MS-TRIP) (pdf file)
    www.ahrq.gov/sites/default/files/2024-02/ornstein-report.pdf
    January 01, 2024 - potentially inappropriate therapy, avoiding potentially inappropriate dosages, avoiding potential drug-drug … drug events. … Practice-level avoidance of potential drug- drug interactions and potentially inappropriate dosages were … interactions, drug-disease interactions, and monitoring or prevention of adverse drug events (ADEs) … drug events.

57. Chronic Obstructive Pulmonary Disease Exacerbations (pdf file)
    www.ahrq.gov/sites/default/files/wysiwyg/antibiotic-use/long-term-care/one-pager-COPD.pdf
    June 02, 2021 - Doxycycline – Drug Summary. … Doxycycline: Drug information. … Food & Drug Administration. … February 2018. https://www.fda.gov/drugs/drug-safety- and-availability/fda-drug-safety-communication- … /contents/doxycycline-drug-information?

58. Final Progress Report: Rural Trial of Clinic Order Entry With Decision Support (pdf file)
    www.ahrq.gov/sites/default/files/2024-07/samore-report.pdf
    January 01, 2024 - Features included on-the-fly drug to drug interaction prompts, automatic allergy and drug intolerance … Drug-drug interaction checker: The drug-drug interaction checker displayed information about potential … Drug names color coded in red indicated a major drug-drug interaction; purple indicated a moderate … interactions Rate # unique potential moderate-to-major drug-drug interactions Person-drug month … Drug-drug interactions: Overall, 148 coumadin-associated potential drug-drug interactions (DDI), 43

59. Final Progress Report: Reducing Adverse Drug Events From Anticoagulants, Diabetes Agents and Opioids in Primary Care (pdf file)
    www.ahrq.gov/sites/default/files/2024-01/wessell2-report.pdf
    January 01, 2024 - Final Progress Report: Reducing Adverse Drug Events From Anticoagulants, Diabetes Agents and Opioids … in Primary Care Final Progress Report Reducing Adverse Drug Events from Anticoagulants, Diabetes … National Action Plan for Adverse Drug Event Prevention. Washington, DC. … Emergency Hospitalizations for Adverse Drug Events in Older Americans. … Increases in Drug and Opioid Overdose Deaths-- United States, 2000-2014.

60. Final Progress Report: TOP-MEDS CERT: Tools for Optimizing Medication Safety (pdf file)
    www.ahrq.gov/sites/default/files/wysiwyg/research/findings/final-reports/21093-Lambert-draft-1.pdf
    November 20, 2017 - , and patient-centered drug information. … Key Words: Medication safety, adverse drug events, statistical methods, opioid dosing, simulation, drug … In the context of drug safety, the discrete-time survival model allows us to use drug exposure as a … Regulators and drug companies seeking a validated pre-approval method for identifying confusing drug … to Drug A exceeds a threshold; and (3) Drug B has an indication that matches an active diagnosis (e.g